andarine

Andarine is a non-steroidal selective androgen receptor modulator (SARM) developed by GTx for the treatment of muscle wasting, osteoporosis, and benign prostatic hyperplasia. It acts as an orally active partial agonist of the androgen receptor, with tissue-selective anabolic effects in muscle and bone while sparing other androgenic tissues. Andarine was designed to competitively block dihydrotestosterone binding in the prostate gland but maintain partial agonist activity to reduce side effects compared to traditional antiandrogens. Clinical development was discontinued after phase 1 trials due to visual disturbances observed in human studies. Andarine has not been approved for medical use and is considered experimental; it is also banned in sports due to its performance-enhancing potential[1][3][6][8].

Brand names

Andarine

Other names

andarineS40503S-40503S 40503